This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
The content of this website has been produced in line with the ELREXFIO®▼ (elranatamab) Summary of Product Characteristics for Great Britain and Northern Ireland. For ELREXFIO®▼ (elranatamab) Prescribing Information for Great Britain and Northern Ireland click here.
Target binding
T-cell activation
Tumor cell lysis
Binding of ELREXFIO® to BCMA on tumour cells and CD3 on T cells is independent of native T cell receptor (TCR) specificity or reliance on major histocompability (MHC) Class 1 molecules1
Cytotoxic T cells are recruited to tumour cells and form a cytolytic synapse, generating a robust T-cell response that is MHC-independent, which may contribute to the ability to overcome tumour escape mechanisms2-5
Cytolytic enzymes such as granzyme B and perforin are released, leading to tumor cell killing.5
Confer tumour specificity
Promote stability
Dampen immunogenicity
Confer tumour specificity with an affinity for BCMA over CD36,7
Preferential binding to BCMA over CD3 promotes tumour specificity over T-cell activation.
Promote stability using a fully human immunoglobulin G (IgG) backbone8,9
Fully human IgG antibody design promotes stability and can prolong circulating half-life.
Dampen immunogenicity with modifications to inhibit fragment crystallisable receptor (FcR) engagement*8,10
Preclinical studies indicate that reduced FcR binding may minimise activation of immune effector cells.
BCMA is a tumour-associated antigen that is universally present on myeloma cells2,3
BCMA is selectively expressed on plasma cells and overexpressed on myeloma cells, with near ubiquitous expression across the multiple myeloma population. It is minimally expressed on haematopoetic stem cells and non-haematopoetic tissue.2
BCMA expression and activation may contribute to multiple myeloma disease progression, promoting tumour cell survival and proliferation.2,11
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024